JPRN-UMIN000024841
Recruiting
未知
A comprehensive surveillance study on the patients with malignant lymphoma undergoing CODOX-M/IVAC regimen with or without rituximab. - A comprehensive surveillance study on the patients with malignant lymphoma undergoing CODOX-M/IVAC regimen with or without rituximab.
ConditionsMalignant lymphoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malignant lymphoma
- Sponsor
- ational Cancer Center Hospital
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients who have a communication problem in Japanese. 2\)Patients who are disqualified by their attending physician. 3\)In the case of questionnaire investigation, patients undergoing second\-line therapy except for additional radiation therapy for residual lesion after CODOX\-M/IVAC with or without rituximab.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Registry study for the surveillance of patients participating in prospective phase I,II or III studies including Ventricular Assist Tissue (VAT)I50Heart failureDRKS00027292niversitätsmedizin Göttingen53
Recruiting
Not Applicable
General Drug Use Surveillance (All Patient Surveillance) of ENSPRYNG Syringes for Subcutaneous Injection - Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)JPRN-UMIN000041047Chugai Pharmaceutical Co. Ltd.330
Active, not recruiting
Phase 1
Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-KetamiEUCTR2006-000767-28-ATVienna Medical University
Completed
Not Applicable
An observational study to investigate patient-reported satisfaction with apixaban when switched from warfarin in Japanese NVAF patients (AGAIN study)on-valvular atrial fibrillationJPRN-UMIN000018970Pfizer Japan Inc.865
Recruiting
Not Applicable
Study to evaluate the occurrence of Dengue in areas with higher concentrations of cases in BrazilDengueC02.081.270RBR-2w55vqGlaxoSmithKline Biologicals